| Characteristic |
Ondansetron (n = 32) |
Placebo (n = 33) |
p |
Plasma GGT, U/L; mean (SD)
(reference range 8-61) |
109.66
(89.71) |
232.39 (491.06) |
t = -1.39, 63 df, p = 0.17 |
Plasma ALT, U/L; mean (SD)
(reference range < 41) |
35.37
(26.24) |
36.06 (29.98) |
t = -0.09, 63 df, p = 0.92 |
Plasma AST, U/L; mean (SD)
(reference range < 37) |
33.97
(23.97) |
47.58 (45.64) |
t = -1.50, 63 df, p = 0.14 |
Plasma MCV, f/L; mean (SD)
(reference range 80-100) |
95.72
(8.60) |
94.74 (6.43) |
t = 0.51, 63 df, p = 0.61 |
| CIWA-AR, mean (SD) |
13.09 (8.87) |
14.24 (9.54) |
t = -0.50, 63 df, p = 0.62 |
| SADD, mean (SD) |
28.41 (8.61) |
24.73 (6.94) |
t = 1.90, 63 df, p = 0.06 |
| OCDS, mean (SD) |
48.47 (8.89) |
44.40 (10.09) |
t = 1.72, 63 df, p = 0.09 |
| HDRS, mean (SD) |
9.01 (5.07) |
10.15 (5.57) |
t = -0.87, 63 df, p = 0.39 |
Biological markers were measured and instruments were applied over two weeks
before the beginning of double-blind study.
GGT: Gamma-Glutamyl Transferase; ALT: Alanine Aminotransferase; AST:
Aspartate Aminotransferase; MCV: Mean Cellular Volume; CIWA-AR: Clinical
Institute Withdrawal Assessment; SADD: Short Alcohol Dependence Data; OCDS:
Obsessive-Compulsive Drinking Scale; HDRS: Hamilton Depression Rating Scale. |
